The rapid proliferation of omics data, which provides essential information regarding bio-molecular activity within cells, is transforming drug discovery. Equipped with this data, DeepLife, a next generation systems biology company, has established a platform for creating digital twins of human cells, enabling scientists to rapidly evaluate how unhealthy cells respond to drug candidates in silico. DeepLife has deployed and established proof-of-concept for its platform, and is now actively seeking partners for target identification and drug repositioning projects enabled by its digital twin technology. All diseases, and efforts to treat them, start at the cellular level. Small changes in the trillions of chemical interactions that make up human cells, which can be triggered by mutations or external forces, can cause cells to enter pathological states that ultimately manifest in diseases.